489 related articles for article (PubMed ID: 22520124)
1. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
Rheingans R; Atherly D; Anderson J
Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
[TBL] [Abstract][Full Text] [Related]
2. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
3. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
4. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
[TBL] [Abstract][Full Text] [Related]
5. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
[TBL] [Abstract][Full Text] [Related]
6. Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People's Democratic Republic.
Rheingans R; Anderson JD; Bagamian KH; Pecenka CJ
Vaccine; 2018 Dec; 36(51):7868-7877. PubMed ID: 30007827
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
8. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Murphy S; Anderson B; Johansson KA; Glass R; Rheingans R
Vaccine; 2013 Oct; 31(42):4902-10. PubMed ID: 23871824
[TBL] [Abstract][Full Text] [Related]
9. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
10. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
11. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
[TBL] [Abstract][Full Text] [Related]
12. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.
Megiddo I; Colson AR; Nandi A; Chatterjee S; Prinja S; Khera A; Laxminarayan R
Vaccine; 2014 Aug; 32 Suppl 1():A151-61. PubMed ID: 25091670
[TBL] [Abstract][Full Text] [Related]
14. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
17. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
18. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities.
Rheingans R; Anderson JD; Anderson B; Chakraborty P; Atherly D; Pindolia D
Vaccine; 2014 Aug; 32 Suppl 1():A140-50. PubMed ID: 25091669
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
20. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.
Widdowson MA; Steele D; Vojdani J; Wecker J; Parashar U
J Infect Dis; 2009 Nov; 200 Suppl 1():S1-8. PubMed ID: 19817589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
